Weight Loss Drugs Wegovy, Ozempic Gain Traction With Millennials, High Earners: New Survey Results
Portfolio Pulse from Chris Katje
Prescription weight loss drugs Ozempic, Wegovy and Mounjaro have seen increased interest in 2023, leading to a rise in the shares of their respective pharmaceutical companies. A survey by Morning Consult reveals that 12% of adults are very interested in these drugs, with heightened interest among well-informed respondents, individuals with weight-related health issues, high-income households, and millennials. Novo Nordisk (NYSE:NVO), the company behind Ozempic and Wegovy, saw shares rise 77% over the last year, while Eli Lilly (NYSE:LLY), the company behind Mounjaro, saw shares rise 62%. Conversely, food and beverage stocks like The Coca-Cola Company (NYSE:KO) and PepsiCo (NYSE:PEP) have seen a drop in shares, possibly due to the influence of weight loss drugs.
October 26, 2023 | 7:40 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The Coca-Cola Company has seen a drop in shares, possibly due to the influence of weight loss drugs.
The rise in interest in weight loss drugs may be leading to a decrease in demand for food and beverage products, negatively impacting The Coca-Cola Company's shares.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
PepsiCo has seen a drop in shares, possibly due to the influence of weight loss drugs.
The rise in interest in weight loss drugs may be leading to a decrease in demand for food and beverage products, negatively impacting PepsiCo's shares.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Walmart, a major seller of food and drink products, has reported a 'slight pullback' in products from customers using weight loss drugs.
The rise in interest in weight loss drugs may be leading to a decrease in demand for food and beverage products, potentially impacting Walmart's sales.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
Eli Lilly, the company behind weight loss drug Mounjaro, has seen its shares rise 62% over the last year.
The increased interest in weight loss drugs has led to a rise in Eli Lilly's shares, indicating a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
POSITIVE IMPACT
Novo Nordisk, the company behind weight loss drugs Ozempic and Wegovy, has seen its shares rise 77% over the last year.
The increased interest in weight loss drugs has led to a rise in Novo Nordisk's shares, indicating a positive impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100